These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26826543)

  • 1. A case for preART-adjusted endpoints in HIV therapeutic vaccine trials.
    Huang Y; Zhang L; Jolliffe D; Hovden AO; Ökvist M; Pantaleo G; Sommerfelt MA
    Vaccine; 2016 Mar; 34(10):1282-8. PubMed ID: 26826543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell-Mediated Immune Predictors of Vaccine Effect on Viral Load and CD4 Count in a Phase 2 Therapeutic HIV-1 Vaccine Clinical Trial.
    Huang Y; Pantaleo G; Tapia G; Sanchez B; Zhang L; Trondsen M; Hovden AO; Pollard R; Rockstroh J; Ökvist M; Sommerfelt MA
    EBioMedicine; 2017 Oct; 24():195-204. PubMed ID: 28970080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.
    Pollard RB; Rockstroh JK; Pantaleo G; Asmuth DM; Peters B; Lazzarin A; Garcia F; Ellefsen K; Podzamczer D; van Lunzen J; Arastéh K; Schürmann D; Clotet B; Hardy WD; Mitsuyasu R; Moyle G; Plettenberg A; Fisher M; Fätkenheuer G; Fischl M; Taiwo B; Baksaas I; Jolliffe D; Persson S; Jelmert O; Hovden AO; Sommerfelt MA; Wendel-Hansen V; Sørensen B
    Lancet Infect Dis; 2014 Apr; 14(4):291-300. PubMed ID: 24525316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postvaccination C-Reactive Protein and C5/gp41
    Huang Y; Zhang L; Jolliffe D; Sanchez B; Stjernholm G; Jelmert Ø; Ökvist M; Sommerfelt MA
    AIDS Res Hum Retroviruses; 2018 Mar; 34(3):307-313. PubMed ID: 29297230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption.
    Rockstroh JK; Asmuth D; Pantaleo G; Clotet B; Podzamczer D; van Lunzen J; Arastéh K; Mitsuyasu R; Peters B; Silvia N; Jolliffe D; Ökvist M; Krogsgaard K; Sommerfelt MA
    PLoS One; 2019; 14(1):e0210965. PubMed ID: 30699178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): Immune responses to Vacc-4x regions on p24 and changes in HIV reservoirs.
    Tapia G; Højen JF; Ökvist M; Olesen R; Leth S; Nissen SK; VanBelzen DJ; O'Doherty U; Mørk A; Krogsgaard K; Søgaard OS; Østergaard L; Tolstrup M; Pantaleo G; Sommerfelt MA
    J Infect; 2017 Dec; 75(6):555-571. PubMed ID: 28917661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A therapeutic HIV-1 vaccine enhances anti-HIV-1 immune responses in patients under highly active antiretroviral therapy.
    Tung FY; Tung JK; Pallikkuth S; Pahwa S; Fischl MA
    Vaccine; 2016 Apr; 34(19):2225-32. PubMed ID: 27002500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intradermal vaccination of HIV-infected patients with short HIV Gag p24-like peptides induces CD4 + and CD8 + T cell responses lasting more than seven years.
    Lind A; Sommerfelt M; Holmberg JO; Baksaas I; Sørensen B; Kvale D
    Scand J Infect Dis; 2012 Aug; 44(8):566-72. PubMed ID: 22339485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial.
    Leth S; Schleimann MH; Nissen SK; Højen JF; Olesen R; Graversen ME; Jørgensen S; Kjær AS; Denton PW; Mørk A; Sommerfelt MA; Krogsgaard K; Østergaard L; Rasmussen TA; Tolstrup M; Søgaard OS
    Lancet HIV; 2016 Oct; 3(10):e463-72. PubMed ID: 27658863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study.
    Harrer T; Plettenberg A; Arastéh K; Van Lunzen J; Fätkenheuer G; Jaeger H; Janssens M; Burny W; Collard A; Roman F; Loeliger A; Koutsoukos M; Bourguignon P; Lavreys L; Voss G
    Vaccine; 2014 May; 32(22):2657-65. PubMed ID: 24144472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.
    Andrés C; Plana M; Guardo AC; Alvarez-Fernández C; Climent N; Gallart T; León A; Clotet B; Autran B; Chomont N; Gatell JM; Sánchez-Palomino S; García F
    J Virol; 2015 Sep; 89(18):9189-99. PubMed ID: 26109727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452).
    Autran B; Murphy RL; Costagliola D; Tubiana R; Clotet B; Gatell J; Staszewski S; Wincker N; Assoumou L; El-Habib R; Calvez V; Walker B; Katlama C;
    AIDS; 2008 Jul; 22(11):1313-22. PubMed ID: 18580611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.
    Rerks-Ngarm S; Paris RM; Chunsutthiwat S; Premsri N; Namwat C; Bowonwatanuwong C; Li SS; Kaewkungkal J; Trichavaroj R; Churikanont N; de Souza MS; Andrews C; Francis D; Adams E; Flores J; Gurunathan S; Tartaglia J; O'Connell RJ; Eamsila C; Nitayaphan S; Ngauy V; Thongcharoen P; Kunasol P; Michael NL; Robb ML; Gilbert PB; Kim JH
    J Infect Dis; 2013 Apr; 207(8):1195-205. PubMed ID: 22837492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic immunisation plus cytokine and hormone therapy improves CD4 T-cell counts, restores anti-HIV-1 responses and reduces immune activation in treated chronic HIV-1 infection.
    Herasimtschuk A; Downey J; Nelson M; Moyle G; Mandalia S; Sikut R; Adojaan M; Stanescu I; Gotch F; Imami N
    Vaccine; 2014 Dec; 32(51):7005-7013. PubMed ID: 25454870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).
    Kilby JM; Bucy RP; Mildvan D; Fischl M; Santana-Bagur J; Lennox J; Pilcher C; Zolopa A; Lawrence J; Pollard RB; Habib RE; Sahner D; Fox L; Aga E; Bosch RJ; Mitsuyasu R;
    J Infect Dis; 2006 Dec; 194(12):1672-6. PubMed ID: 17109338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon α-2a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial.
    Leal L; Couto E; Sánchez-Palomino S; Climent N; Fernández I; Miralles L; Romero Y; González T; Maleno MJ; Paño B; Pich J; Nicolau C; Gatell JM; Plana M; García F;
    Front Immunol; 2021; 12():767370. PubMed ID: 34858423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Classifier to Predict Viral Control After Antiretroviral Treatment Interruption in Chronic HIV-1-Infected Patients.
    Fehér C; Plana M; Crespo Guardo A; Climent N; Leal L; Ugarte A; Fernández I; Etcheverry MF; Gatell JM; Sánchez-Palomino S; García F; Aloy P
    J Acquir Immune Defic Syndr; 2020 Apr; 83(5):479-485. PubMed ID: 31904703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Jacobson JM; Routy JP; Welles S; DeBenedette M; Tcherepanova I; Angel JB; Asmuth DM; Stein DK; Baril JG; McKellar M; Margolis DM; Trottier B; Wood K; Nicolette C
    J Acquir Immune Defic Syndr; 2016 May; 72(1):31-8. PubMed ID: 26751016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946).
    Kundu-Raychaudhuri S; Sevin A; Kilgo P; Nokta M; Pollard RB; Merigan TC
    AIDS Res Hum Retroviruses; 2001 Oct; 17(15):1371-8. PubMed ID: 11679149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy.
    Asjö B; Stavang H; Sørensen B; Baksaas I; Nyhus J; Langeland N
    AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1357-65. PubMed ID: 12487807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.